Medicine Information

Lyrinex-CR

Name: Lyrinex-CR
Brand: Lyrinex-CR
Rating: 4.5 (117 reviews)

Controlled-release Tablet825 mgAnticonvulsant, Neuropathic pain agentATC: N03AX16

Generic Name

lyrinex-cr-825-mg-tablet

Manufacturer

PharmaCo Bangladesh Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
lyrinex cr 825 mg tablet	৳ 18.00	৳ 180.00

Description

Overview of the medicine

Lyrinex-CR 825 mg Tablet is a controlled-release formulation of pregabalin, primarily used to manage neuropathic pain, fibromyalgia, and as an adjunctive therapy for partial onset seizures in adults. Its extended-release nature allows for less frequent dosing.

Uses & Indications

Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia)

Fibromyalgia

Adjunctive therapy for partial onset seizures in adults

Dosage

Adults

Dosage must be individualized based on patient response and tolerability. For CR formulation, typically once daily. 825 mg is above typical maximum doses for pregabalin and requires careful monitoring as per prescribing information.

Elderly

Dosage adjustments may be necessary due to potential age-related decline in renal function. Start with a lower dose and titrate slowly.

Renal_impairment

Significant dose reduction is required for patients with impaired renal function (creatinine clearance <60 mL/min). Dosing frequency may also need adjustment.

How to Take

Take orally with or without food. Swallow the tablet whole; do not crush, chew, or split. Administer once daily, preferably at the same time each day.

Mechanism of Action

Pregabalin binds to the alpha2-delta (α2-δ) subunit of voltage-gated calcium channels in the central nervous system, thereby modulating the release of several neurotransmitters including glutamate, norepinephrine, and substance P. This action is believed to reduce hyperexcitability and nerve pain.

Pharmacokinetics

Onset

Clinical effects typically observed within 1-2 weeks, with pain relief sometimes seen earlier. Full effect might take longer.

Excretion

Primarily excreted unchanged in the urine. Renal excretion is the major elimination route.

Half life

Approximately 6.3 hours. For CR formulations, effective half-life can be longer due to sustained release.

Absorption

Well absorbed orally, high bioavailability (≥90%). Peak plasma concentration for CR formulation is typically reached within several hours. Food may delay absorption but does not significantly affect total absorption.

Metabolism

Negligible hepatic metabolism in humans; less than 0.1% of the dose is metabolized.

Side Effects

Contraindications

Hypersensitivity to pregabalin or any component of the formulation
Patients with a history of angioedema with previous pregabalin or gabapentin treatment

Drug Interactions

Opioids

Increased risk of respiratory depression and sedation.

ACE inhibitors

Potentiates the risk of angioedema.

Benzodiazepines

Increased risk of sedation and CNS depression.

Storage

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Overdose

Symptoms of overdose include somnolence, confusion, agitation, and restlessness. Management is primarily supportive; gastric lavage or emesis may be considered. Hemodialysis is an effective method for removing pregabalin.

Pregnancy & Lactation

Pregnancy Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Not recommended during breastfeeding as it is excreted in breast milk.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per blister30 tablets per box

Shelf Life

24 months from manufacturing date

Availability

Pharmacies and hospitals

Approval Status

Approved by regulatory authorities

Patent Status

Patent expired for generic Pregabalin, brand formulation may have protection

Clinical Trials

Extensive clinical trials have established the efficacy and safety of pregabalin for its approved indications. Specific trials for an 825 mg CR formulation would be conducted by the manufacturer.

Lab Monitoring

Renal function tests (e.g., creatinine clearance) periodically, especially in elderly and renally impaired patients
Regular monitoring for signs of CNS depression and suicidal ideation

Doctor Notes

Counsel patients on the risk of CNS depression when co-administered with other depressants.
Advise patients about potential for suicidal thoughts and to report any such changes.
Gradual tapering is crucial to avoid withdrawal seizures and other symptoms.

Patient Guidelines

Do not stop taking this medicine abruptly, as it may lead to withdrawal symptoms.
Report any unusual mood changes, suicidal thoughts, or signs of allergic reaction (e.g., swelling of face, lips, or throat) immediately.
Avoid driving or operating machinery until you know how this medicine affects you.

Missed Dose Advice

If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

Driving Precautions

May cause dizziness, somnolence, and blurred vision, impairing the ability to drive or operate machinery. Patients should be advised to exercise caution until they are familiar with the drug's effects.

Lifestyle Advice

Maintain a healthy diet and regular exercise.
Avoid alcohol consumption while on this medication as it may increase side effects.
Inform your doctor about all other medications and supplements you are taking.